Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2009

01-01-2009 | Original Article

Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer

Authors: Luiz Carlos Conti-Freitas, Maria Cristina Foss-Freitas, Rui Celso Martins Mamede, Norma Tiraboschi Foss

Published in: Cancer Immunology, Immunotherapy | Issue 1/2009

Login to get access

Abstract

Background

Evaluate the production of TNF and IL-6 in the supernatant of peripheral blood mononuclear cell (PBMC) cultures of patients with supraglottic laryngeal cancer before and after surgical treatment.

Materials and methods

Adherent cell cultures were stimulated with LPS and BCG. Fourteen patients with advanced supraglottic laryngeal cancer were studied. Cytokine concentration was determined by ELISA in supernatants of mononuclear cell cultures.

Results

In non-stimulated cultures, lower TNF cytokine levels were detected during the late postoperative (LP) period compared to control (P = 0.02). LP TNF and IL-6 levels were high in cultures stimulated with LPS compared with the preoperative period (PREOP) (P = 0.007; P = 0.008, respectively). Stimulation with BCG led to increased levels of TNF and IL-6 during the LP period compared to control (P = 0.001; P = 0.04, respectively).

Conclusion

BCG is able to modulate the immune response of patients with advanced supraglottic laryngeal cancer in vitro, increasing the secretion of TNF and IL-6 by macrophages during the postoperative period.
Literature
1.
Ballou SP, Lozanski G (1992) Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4:361–368PubMedCrossRef
2.
Bemelmans MHA, Van Tits LJH, Buurman WA (1996) Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 16:1–11PubMed
3.
Carswell EA, Old LJ, Kassel RL, Green S, Fiori N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666PubMedCrossRef
4.
Chretien PB (1975) Unique immunobiological aspects of head and neck squamous carcinoma. Can J Otolaryngol 4:222–235
5.
Conti-Freitas LC, Foss-Freitas MC, Mamede RCM, Foss NT (2007) Effect of surgical treatment on lymphoproliferation in advanced supraglottic aryngeal cancer. Laryngoscope 117(2):268–272PubMedCrossRef
6.
Coulie PG (1997) Human tumors are recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 3:261–268PubMedCrossRef
7.
Dietz A, Heimlich F, Daniel V, Polarz H, Weidauer H, Maier H (2000) Immunomodulating effects of surgical intervention in tumors of head and neck. Otolaryngol Head Neck Surg 123(1):132–139PubMedCrossRef
8.
Donaldson RC (1972) Methotrexate plus bacillus calmette-guerin (BCG) and isoniazid in treatment of cancer of head and neck. Am J Surg 124:527–532PubMedCrossRef
9.
Foss MC, Foss NT, Paccola GMGF, Silva CL (1992) Serum levels of tumor necrosis factor in insulin-dependent diabetic patients. Braz J Med Biol Res 25:239–242PubMed
10.
Gabay C, Krushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 11:448–454CrossRef
11.
Gallo O, Libonati GA, Gallina E, Fini-Storchi O, Giannini A, Urso C, Bondi R (1991) Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 117:1007–1010PubMed
12.
Gauldie J, Richards C, Lansdoro P, Baumann H (1987) Interferon-β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251–7255PubMedCrossRef
13.
Katz AE (1983) Immunobiologic staging of patients with carcinoma of head and neck. Laryngoscope 93:445–463PubMed
14.
Kursrock R (2001) Cytokine deregulation on cancer. Biomed Pharmacother 55:543–547CrossRef
15.
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273PubMedCrossRef
16.
Marrack FM, Mitchell T, Hilceman D, Kedl R, Teague K, Kappler J (1998) T-cell survival. Immunol Rev 165:279–85PubMedCrossRef
17.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 137:2348–2357
18.
Razack AH (2007) Bacillus Calmette-Guerin and bladder cancer. Asian J Surg 30(4):302–309PubMed
19.
Schantz SP, Liu FJ (1989) An immunologic profile of young adults with head and neck cancer. Cancer 64:1232–1237PubMedCrossRef
20.
Scully C (1982) The immunology of cancer of head and neck with particular reference to oral cancer. Oral Surg 53:157–169PubMedCrossRef
21.
Teague TK, Marrack P, Kappler JW, Vella AT (1997) IL-6 rescues resting mouse T cells from apoptosis. J Immunol 158:5791–5796PubMed
22.
Volanakis JE (1997) Acute phase proteins in rheumatic disease. In: Koopman W (ed) Arthritis and allied conditions: a textbook of rheumatology, 13th edn. Willians & Wilkins, Baltimore, pp 505–514
23.
Wilson AG, Giovine FS, Duff GD (1995) Genetics of tumor necrosis factor-α in autoimmune, infection, and neoplastic diseases. J Inflamm 45:1–12PubMed
Metadata
Title
Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer
Authors
Luiz Carlos Conti-Freitas
Maria Cristina Foss-Freitas
Rui Celso Martins Mamede
Norma Tiraboschi Foss
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0520-7

Other articles of this Issue 1/2009

Cancer Immunology, Immunotherapy 1/2009 Go to the issue

Original Article

In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients

Review

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

Original Article

Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity

Short Communication

Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

Original Article

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

Original Article

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits